Build the
Evidence That
Moves the Deal.
Nectid helps clinical-stage biotech companies determine what evidence
will cause a specific counterparty to fund, option, license, or advance
an asset—and then aligns business development, development strategy,
and capital around that decision.
Powered by TSCIP
Development designed backward from the transaction.
Science identifies the opportunity.
Evidence defines what’s underwritable. Validation defines market need. Capital defines who funds the proof.
SCIENCE
Evidence
Capital
Transaction
The Problem
Good Science Does
Not Automatically Create a Transaction.
01
The biology is compelling.
02
Early clinical data are encouraging.
03
Pharma expresses interest.
04
But the transaction does not happen.
The Decision-Evidence Gap
A potential partner may require evidence the current program was never designed to produce.
The gap is rarely about whether the science is good. It is about whether a specific decision-maker can underwrite the remaining uncertainty.
E01
Monotherapy activity
E02
Combination attribution
E03
Additional safety exposure
E04
Evidence in another tumor state
E05
Defined regulatory path
E06
CMC readiness
E07
Specific proof points
Generating everything is expensive.
Generating the right evidence can change the asset.
TSCIP
Development Designed Backward From the Transaction.
TSCIP is Nectid's proprietary BD-led development platform. It starts from the decision a counterparty has to make and works backward into the development plan.
Traditional Development
- Mechanism
- Preclinical Data
- Mechanism
- Clinical Development
TSCIP
- Potential Counterparty
- Investment Decision
- Evidence Requirement
- Development Plan
- Source of Capital
“What study should we run next?”
What is the smallest credible evidence package that would change the next important Capital or partnering decision?
Evaluation Framework
What TSCIP Evaluates
01
Mechanistic rationale
02
Tumor-state biology
03
Independent drug activity
04
Combination attribution
05
Therapeutic index
06
Transferability across therapeutic backbones
07
Competitive positioning
08
Partner substitution risk
09
Clinical differentiation
10
Regulatory strategy
11
Development timing
12
CMC readiness
13
Pharma strategic fit
14
Evidence required for partner re-engagement
15
Development-capital requirements
16
Potential sources of external capital
One Operating System
The TSCIP Operating Model
Science. Field Validation. Evidence. Capital. Transaction.
01
01
02
03
04
05
06
Asset Assessment
Strengths, critical uncertainties, partnerability, evidence gaps and capital requirements.
Counterparty Mapping
Which specific companies could act, and on which dimension of strategic fit.
Field BD Validation
Direct engagement to learn what would actually change the counterparty's decision.
Evidence Architecture
The minimum credible evidence package required to cross the identified gate.
Capital Routing
Who should finance that evidence, and through which structure.
Transaction Execution
Carrying the validated thesis into a defined strategic transaction.
Field BD Validation
BD Is Not the Final Step. It Is Part of Development.
Counterparty feedback is treated as development data. It defines the evidence gap, which defines the plan, which defines the capital required.
- What would cause the counterparty to advance?
- What additional evidence is required?
- What would cause the counterparty to fund development?
The Feedback Loop
- Counterparty feedback
- Evidence gap
- Development Plan
- Capital
- New evidence
- Counterparty re-engagement
Structure
Two Funnels. One Objective.
Funnel 01
Strategic Partnering
Identify companies for which the asset creates strategic value.
- Asset
- Counterparties
- Engagement
- Validation
- Transaction
Funnel 02
Evidence Financing
Identify who should finance the evidence required to unlock the transaction.
- Evidence Gap
- Capital Source
- Development
- Evidence
- Transaction
- Transaction
Decision Output
Advance. Modify. Hold. Defer.
Every engagement resolves to a stated recommendation, with the reasoning made explicit.
Advance
Evidence and market validation justify continued investment.
Advance
Evidence and market validation justify continued investment.
Advance
Evidence and market validation justify continued investment.
Advance
Evidence and market validation justify continued investment.
Capital discipline, not development for its own sake.
Who We Work With
Three Positions. One Framework.
Asset Holders
Turn Partner Interest Into an Actionable Development Strategy.
Convert informal pharma interest into a defined evidence requirement, a costed development plan and a funding route.
Pharma Partners
Find Assets Through the Evidence That Matters.
Evaluate opportunities against the proof points your committees actually underwrite, with the gaps stated openly.
Development-Capital Partners
Finance an Identified Evidence Gap.
Deploy capital against a specific, validated evidence requirement with a defined transaction pathway on the other side.
Track Record
Built From Transaction Experience.
A Nectid-originated therapeutic combination concept was developed into a defined intellectual property position, supported by a development rationale framed around the requirements of a strategic counterparty already active in the therapeutic area.
The programme was subsequently transacted to Grünenthal. The work illustrates the sequence Nectid applies: identify the therapeutic opportunity, create a defensible position, define the evidence a specific counterparty would need, and run the process to a decision.
Capabilities
Menu
Navigate
Menu